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Abstract: Antibiotic treatments initiated on Emergency Departments (ED) are empirical. Therefore,
knowledge of local susceptibility patterns is important. Despite this, data on expected pathogens
and their resistance profile are scarce from EDs internationally. The study aim was to assess the
epidemiology and resistance patterns of bacterial isolates from a tertiary-care ED over 5 years, focusing
on ESKAPE bacteria (including the Enterobacterales group). After removal of duplicates, n = 6887
individual bacterial isolates were recovered, out of which n = 4974 (72.22%) were ESKAPE isolates.
E. coli was the most frequent isolate (2193, 44.1%), followed by the Klebsiella genus (664; 13.4%).
The third most frequent isolate was S. aureus (561, 11.3%). In total, multi-drug resistance (MDR) was
present in 23.8% and was most prevalent in A. baumanii (65.5%), P. mirabilis (42.7%), and K. pneumoniae
(32.6%). MRSA was isolated in 19.6%, while ESBL-producing Enterobacterales in 17.7%, and these
were associated with remarkably higher resistance to other antibacterials as well. Difficult-to-treat
resistance (DTR) was detected in 0.5%. The frequent isolation of some ESKAPE bacteria and the
detected considerable acquired resistance among ED patients raise concern. The revealed data
identified problematic pathogens and will guide us to set up the optimal empiric antibiotic protocol
for clinicians.
Keywords: antimicrobial resistance; ESKAPE; emergency department; epidemiology; empirical antibiotic
guide; usual drug resistance; UDR; difficult-to-treat resistance; DTR; MDR; XDR; resistance indicators
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1. Introduction
Antimicrobial resistance (AMR) is a serious threat to public health worldwide. Comprehensive
knowledge on the burden and associated outcomes of multi-drug-resistant (MDR) infections is
still lacking. Nevertheless, several studies revealed the association between infections caused by
antibiotic-resistant bacteria and negative patient outcomes, such as longer hospital stays, higher
morbidity and mortality [1–4]. Infections caused by MDR pathogens are often needed to be treated with
more expensive and/or more toxic agents (e.g., colistin, daptomycin) [5,6], which may also affect patient
outcomes. The financial burden of AMR is also considerable [2,7], one case of infection caused by an
AMR pathogen (e.g., an MRSA blood stream infection) can cost up to 20,000 US dollars [2]. AMR is an
increasing problem not only in hospitals, but also in community-acquired infections, associated with
the successful penetration and spread of MDR clones from nosocomial settings [8].
Based on overall mortality and economic impact, the so-called “ESKAPE” group of pathogens deserve
the utmost attention, both from clinical and from research and development aspect [9,10]. Rice introduced
the ESKAPE acronym in 2008 for the group of pathogens capable of ‘escaping’ the biocidal action
of antibiotics, namely E: Enterococcus faecium, S: Staphylococcus aureus, K: Klebsiella pneumoniae, A:
Acinetobacter baumannii, P: Pseudomonas aeruginosa, E: Enterobacter spp [11]. These pathogens rank among
the most prevalent causes of life-threatening infections, and their ability to acquire and disseminate
antimicrobial resistance is well known [12,13]. Recently, the World Health Organisation (WHO)
developed a global priority list of antibiotic-resistant pathogens to guide new antibiotic discovery,
where certain antibiotic resistance in the Enterobacterales family is listed among the critical priorities
(e.g., third generation cephalosporin-resistant Enterobacterales) [14]. Hence, in some publications,
the entire Enterobacterales group is often added to the ESKAPE group of bacteria [15,16] and the letter
‘S’ may be complemented by Stenotrophomonas maltophilia, as that has emerged as global opportunistic
human Gram-negative pathogen [17].
One of the main drivers behind the development of AMR is the misuse and overuse of antibacterial
agents [18,19]. As the utilisation of antibacterials can be controlled [20], rationalization of use is of pivotal
importance to curb AMR. Emergency care departments (EDs) are unique in the health care system,
providing an interface between ambulatory care and hospital care settings [21]. Physicians work at ED
under substantial time-pressure [22]. Moreover, in contrast to General Practitioners, ED physicians
should make decisions on antibiotic prescribing based on limited background information on the patient.
With high rates of patient turn-over, variability in staffing and a subsequent lack of ‘continuity of care’
are important challenges in facilitating prudent use of antibiotics [23]. Out-of-hour services and EDs has
been associated with lower threshold for antibiotic prescribing and suboptimal antibiotic choice [24–28].
Antibiotic treatments initiated on EDs are almost exclusively empirical. Therefore, the knowledge of
local susceptibility patterns is of crucial importance in the antimicrobial stewardship [21,29]. Moreover,
research has found that both isolated bacteria and related antibiotic susceptibility patterns differ
between isolates originating from the ED and cultures obtained in other hospitalized patients, hence
general hospital resistance maps may not serve as optimal guide for empirical treatment initiated at
ED [30]. Despite this, data on expected pathogens and their resistance profile in community-acquired
infections [31] and specifically data from ED are scarce.
Therefore, the aim of the present study was to assess the epidemiology and resistance patterns
of bacterial isolates from the ED that may help to identify problematic pathogens and to set up an
optimal empiric antibiotic guide for clinicians.
2. Results
2.1. Distribution of Bacterial Isolates
During the study period, n = 6887 individual bacterial isolates were recovered from clinical
specimens, out of which n = 4974 (72.22%) were ESKAPE pathogens. Overall, as shown in Table 1,
we observed the dominance of Gram-negative bacteria. The Enterobacterales group was predominant
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among all ESKAPE isolates, with 75% of all isolates being from this group. Escherichia coli was the most
frequently isolated bacteria (2193, 44.1%), followed by the Klebsiella genus (664; 13.4%), most frequently
K. pneumoniae. The third most frequent isolate was S. aureus (561, 11.3%), followed by Proteus spp. (526,
10.57%). Stenotrophomonas maltophilia, A. baumannii, and the Providencia, Salmonella and Serratia genus
played limited role, with below 1% of share within the ESKAPE group.
Table 1. Epidemiology and distribution of ESKAPE pathogens during the study period.
Gram Stain Bacterial Family/Genus/Species Frequency (%)
Gram-positive
n = 1032 (20.75%)
Enterococcus spp. 471 (9.47%)
Staphylococcus aureus 561 (11.28%)
Gram-negative
n = 3942 (79.25%)
Stenotrophomonas maltophilia 4 (0.08%)
Klebsiella spp. 664 (13.35%)
Acinetobacter baumannii 31 (0.62%)
Pseudomonas aeruginosa 181 (3.64%)
Enterobacterales: Escherichia spp. 2194 (44.11%)
Enterobacterales: Proteus spp. 526 (10.57%)
Enterobacterales: Enterobacter spp. 119 (2.39%)
Enterobacterales:Morganella spp. 75 (1.51%)
Enterobacterales: Citrobacter spp. 53 (1.07%)
Enterobacterales: Providencia spp. 40 (0.8%)
Enterobacterales: Salmonella spp. 33 (0.66%)
Enterobacterales: Serratia spp. 22 (0.44%)
Total 4974 (100%)
The most frequent clinical specimens were blood cultures, urinary catheter or midstream urine
specimens, and deep wound or abscess samples (Table 2). Respiratory samples were only taken rarely
(n = 121) mainly from critically ill patients. We observed the dominance of Escherichia isolates in blood
and urine samples. In blood cultures, S. aureus was the second most frequent isolate, whereas in urine
the Klebsiella genus. In wound/abscess specimens S. aureus were isolated most often, followed by the
Proteus spp.
2.2. Bacterial Resistance According to Specific Indicators
The overall resistance level of the ESKAPE isolates is summarized in Table 3. In total more
than half of the isolates (55.31%) possessed intrinsic resistance only (i.e., wild type), however these
ranged between 12.9%% (A. bauminii) and 84.85%% (Salmonella genus) among different isolates.
Usual drug resistance (UDR) was developed in 44.69%% of isolates, and ranged between 15.15%%
(Salmonella spp.) and 87.10%% (A. bauminii). UDR was prevalent among the most frequently isolated
bacteria (i.e., E. coli and Klebsiella spp.). Multi-drug resistance (MDR) was acquired in almost every
fourth isolate and showed considerable range between different ESKAPE isolates (Figure 1). MDR was
most prevalent in A. bauminii, followed by Proteus, Klebsiella, and Escherichia spp. and lowest in
Salmonella spp. For the most frequently isolated Gram-positive bacteria, S. aureus, the prevalence
of MDR was nearly 20%. For the Enterococcus genus MDR was detected on average in 3.83%%,
but species-level data showed extreme diversity (see below). DTR was present in 23 isolates (among
which, Klebsiella spp., A. baumannii, P. aeruginosa, and Proteus spp. were implicated) while we detected
only one pandrug-resistant P. aeruginosa isolate.
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Table 2. Distribution of ESKAPE isolates by clinical specimens.
Acro-nym Bacterial Family/Genus/Species Blood Culture(%)
Catheter-Specimen Urine
(%)
Midstream Urine
(%)
Wound or Abscess
(%)
Others
(%)
Total
(%)
E Enterococcus spp. 93 (19.7%) 191 (40.6%) 76 (16.1%) 48 (10.2%) 63 (13.4%) 471 (100%)
S
Staphylococcus aureus 252 (64.5%) 12 (3.1%) 6 (1.5%) 121 (30.9%) 0 (0%) 391 (100%)
Stenotrophomonas maltophilia (0%) 1 (0.6%) (0%) 3 (1.7%) 170 (97.7%) 174 (100%)
K Klebsiella spp. 212 (31.9%) 234 (35.2%) 118 (17.8%) 49 (7.4%) 51 (7.7%) 664 (100%)
A Acinetobacter baumannii 6 (19.4%) 6 (19.4%) (0%) 5 (16.1%) 14 (45.2%) 31 (100%)
P Pseudomonas aeruginosa 47 (26%) 53 (29.3%) 16 (8.8%) 25 (13.8%) 40 (22.1%) 181 (100%)
E
Enterobacterales: Citrobacter spp. 13 (24.5%) 17 (32.1%) 7 (13.2%) 9 (17%) 7 (13.2%) 53 (100%)
Enterobacterales: Enterobacter spp. 27 (22.7%) 30 (25.2%) 9 (7.6%) 24 (20.2%) 29 (24.4%) 119 (100%)
Enterobacterales: Escherichia spp. 676 (30.8%) 823 (37.5%) 531 (24.2%) 75 (3.4%) 89 (4.1%) 2194 (100%)
Enterobacterales:
Morganella morganii 25 (33.3%) 11 (14.7%) 2 (2.7%) 21 (28%) 16 (21.3%) 75 (100%)
Enterobacterales: Proteus spp. 116 (22.1%) 174 (33.1%) 44 (8.4%) 99 (18.8%) 93 (17.7%) 526 (100%)
Enterobacterales: Providencia spp. 6 (15%) 15 (37.5%) 2 (5%) 8 (20%) 9 (22.5%) 40 (100%)
Enterobacterales: Salmonella spp. 29 (87.9%) 3 (9.1%) 1 (3%) 0 (0%) 0 (0%) 33 (100%)
Enterobacterales: Serratia spp. 5 (22.7%) 1 (4.5%) 2 (9.1%) 7 (31.8%) 7 (31.8%) 22 (100%)
Total 1507 (30.3%) 1571 (31.6%) 814 (16.4%) 494 (9.9%) 588 (11.8%) 4974 (100%)
Others = skin, cerebrospinal fluid, respiratory.
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Table 3. Antibiotic resistance levels of ESKAPE isolates during the study period.
Bacterial
Family/Genus/Species
Isolates
(100%) Wt (%) UDR (%) MDR (%) DTR (%) XDR (%)
Enterococcus spp. 471 18 (3.82%) 0 (0%)
Staphylococcus aureus 561 110 (19.61%) 0 (0%)
Stenotrophomonas maltophilia 4 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Klebsiella spp. 664 390 (58.73%) 274 (41.27%) 182 (27.41%) 1 (0.15%) 0 (0%)
Acinetobacter baumannii 31 4 (12.90%) 27 (87.10%) 21 (67.74%) 13 (41.94%) 0 (0%)
Pseudomonas aeruginosa 181 117 (64.64%) 64 (35.36%) 24 (13.26%) 8 (4.42%) 1 (0.55%)
Citrobacter spp. 53 38 (71.70%) 15 (28.30%) 6 (11.32%) 0 (0%) 0 (0%)
Enterobacter spp. 119 79 (66.39%) 40 (33.61%) 14 (11.76%) 0 (0%) 0 (0%)
Escherichia spp. 2194 891 (40.61%) 1303 (59.39%) 572 (26.07%) 0 (0%) 0 (0%)
Morganellas spp. 75 12 (16%) 63 (84.00%) 14 (18.67%) 0 (0%) 0 (0%)
Proteus spp. 526 129 (24.52%) 397 (75.48%) 214 (40.68%) 1 (0.19%) 0 (0%)
Providencia spp. 40 14 (35%) 26 (65.00%) 5 (12.50%) 0 (0%) 0 (0%)
Salmonella spp. 33 28 (84.85%) 5 (15.15%) 0 (0%) 0 (0%) 0 (0%)
Serratia spp. 22 13 (59.09%) 9 (40.91%) 3 (13.64%) 0 (0%) 0 (0%)
Total 4974 2751 (55.31%) 2223 (44.69%) 1183 (23.78%) 23 (0.46%) 1 (0.02%)
Wt: wild type, UDR: usual drug resistance, MDR: multi-drug resistance, DTR: difficult to treat resistance, XDR:
extensively drug-resistant.Antibiotics 2020, 9, x FOR PEER REVIEW 6 of 18 
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Figure 1. Rate of multi-drug resistance among ESKAPE isolates.
2.3. Bacterial Resistance to Specific Antibacterials
Table 4 (for Gram-positive bacteria) and Table 5 (for Gram-negative bacteria) show the susceptibility
rate of ESKAPE isolates to specific antibiotics and MDR rates at species-level. E. fae alis species can
be effectivel treated with first line agent su h as ampicillin, as all isolates proved to b susceptible.
In contrast, in case of E. faecium isolates, the c ical success can be ant pated in case of tigecycline and
linezolid, which are both reserve antibacterial agents based on in-vitro data. Vancomycin resist nce
among E. faecium was detected in every third case, while MDR c n be encount red in nearly every
second isolate (45.5%). Methicilin-resistant S. aureus (MRSA) w re isolated in 19.6% (95/561). Over the
years, no clear increasing or decreasing tr nd for MRSA has be n observed (data not shown).
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Methicillin-resistant strains (MRSA) were also considerably less susceptible to many other antibacterial
agents (see Table 4) compared to methicillin-susceptible strains (MSSA). Effective treatment for MRSA
can be anticipated by sulfamethoxazol-trimethoprim or glycopeptides.
Table 4. Rates of susceptibility and multi-drug resistance for Gram-positive ESKAPE isolates.
OXA AMP CC CIP * ERY GM LNZ TEC VA TGC SXT MDR
Enterococcus faecalis IR 100.0 IR 56.8 IR IR 99.1 100.0 100.0 99.3 IR 0.7
Enterococcus faecium IR IR IR 7.1 IR IR 100.0 78.8 66.7 100.0 IR 45.5
Staphylococcus aureus 83.1 IR 79.4 80.7 78.0 98.6 100.0 100.0 100.0 100.0 98.6 19.6
MSSA - IR 89.2 92.8 88.2 99.4 100.0 99.8 100.0 100.0 98.7 3.2
MRSA - IR 30.9 22.1 27.7 94.7 100.0 100.0 100.0 100.0 97.9 100.0
*: relevant only for urinary specimens, IR = intrinsic resistance, OXA = oxacillin, AMP = ampicillin, CC = clindamycin;
CIP = ciprofloxacin; ERY = erythromicin; GM = gentamicin; LNZ = linezolid; TEC = teicoplanin; VA = vancomycin,
TGC = tigecyclin; SXT = sumetrolim; MSSA = methicillin sensitive S. aureus; MRSA = methicillin-resistant S. aureus.
Green: susceptibility rate over 90%, may be prescribed empirically even in severe infections, Yellow: susceptibility
rate over 80%, may be prescribed empirically except severe infection, Red: should not be prescribed empirically.
If an isolate is susceptible in high rate to certain antibiotics (e.g., MSSA to ciprofloxacin or to gentamicin) it does
not mean that the antibiotic is a recommended agent. If an isolate is susceptible in low rate to certain antibiotics
(e.g., Enterococcus faecium to vancomycin) it does not mean that the agent cannot be used in selected cases.
Different Klebsiella species showed different resistance levels to certain antibacterials (Table 5).
K. pneumoniae isolates had low susceptibility rate (below 70% or 80%) to all beta-lactams except
carbapenems (indicative of ESBL production) and presence of MDR in every third isolate (32.6%).
A. baumannii isolates showed high resistance level to all tested antibacterials, except the reserve
antibiotic colistin to which all tested organisms (n = 15) were fully susceptible. P. aeruginosa strains
were highly susceptible to ceftazidime (90.6%), cefepime (91.7%), and aminoglycosides (over 90%)
and clinical success can be anticipated by also piperacilin-tazobactam empirical treatment, as overall
susceptibility rate was 87.2%. Out of the four P. aueruginosa isolates that were tested for colistin,
one isolate, considered extensively drug-resistant (XDR) was resistant to colistin.
E. coli, the most frequently isolated Gram-negative bacteria were susceptible to aminoglycosides in
~90% (see Table 5). Co-amoxiclav, cefuroxime, and third generation cephalosporin susceptibility among
E. coli isolates ranged between 80% and 90%. Based on the susceptibility rates, the treatment of infections
caused by P. mirabilis are cumbersome (susceptibility to different beta lactam agents ranged between
40.4% and 75.5%, while ciprofloxacin susceptibility was 57.7%), while P. vulgaris strains were highly
susceptible (over 90%) to many beta-lactam agents (see Table 5). ESBL-positive Enterobacterales strains
(659/3719; 17.7%) were generally less susceptible to non-beta lactam antibacterial agents compared to
ESBL-negative strains. Concerning the whole Enterobacterales group, no clear temporal trend in the
rate of ESBL-positive strains has been observed (ranged between 14.6% and 20.5%, data not shown).
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Table 5. Rates of susceptibility and multi-drug resistance for Gram-negative ESKAPE isolates.
AMP AMC CXM CTX CAX CAZ FEP TZP ETP MEM CIP AK GM SXT MDR
Klebsiella aerogenes 0.0 IR 66.7 75.0 80.6 80.6 85.7 80.0 100.0 100.0 87.1 100.0 96.8 93.5 22.6
Klebsiella oxytoca 0.0 91.1 96.8 98.0 97.5 97.5 98.0 98.0 100.0 100.0 100.0 98.0 100.0 98.7 2.53
Klebsiella pneumoniae 0.0 67.5 67.2 73.0 69.4 69.4 76.6 76.1 99.8 99.8 62.8 79.3 79.1 65.5 32.6
Klebsiella variicola 0.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 0.0
Acinetobacter baumannii NT IR NT NT IR NT NT NT IR 55.2 13.8 37.9 40.7 21.4 65.5
Pseudomonas aeruginosa NT IR NT NT IR 90.6 91.7 87.2 IR 85.6 77.9 96.7 90.1 NT 13.3
Citrobacter freundii 0.0 IR 20.0 82.4 71.4 71.4 82.4 82.4 100.0 100.0 90.5 100.0 100.0 100.0 19
Citrobacter koseri 0.0 81.5 77.3 100.0 100.0 100.0 100.0 85.7 100.0 100.0 100.0 100.0 100.0 100.0 3.7
Enterobacter cloacae 0.0 IR 38.8 84.4 83.0 83.0 84.4 84.1 100.0 100.0 93.3 98.4 98.9 93.2 11.2
Escherichia coli 48.5 81.8 85.4 85.8 86.1 86.2 86.7 85.0 100.0 100.0 67.9 89.2 90.3 72.7 26.1
Morganella morganii 0.0 IR 0.0 93.3 90.3 90.3 93.3 90.0 100.0 100.0 90.3 91.5 91.7 72.2 18.1
Proteus mirabilis 40.4 62.3 63.0 71.7 69.1 69.1 75.5 74.7 99.8 100.0 57.7 75.7 77.2 32.1 42.7
Proteus vulgaris 0.0 40.0 0.0 95.5 91.4 91.4 95.5 95.5 100.0 100.0 85.7 95.5 91.4 65.7 14.3
Providencia stuartii 0.0 IR 31.6 93.3 96.6 96.6 92.9 92.9 100.0 100.0 72.4 36.4 28.6 29.6 17.2
Salmonella spp. 90.6 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 96.0 100.0 100.0 96.9 0.0
Enterobacterales 34.6 70.4 76.0 83.1 82.3 82.3 84.9 83.5 99.9 100.0 69.4 86.1 87.5 68.5 27.1
Enterobacterales non ESBL 100.0 100.0 82.2 93.5 93.8 77.1 11.8
Enterobacterales ESBL 99.7 99.8 9.6 46.8 58.6 27.9 98.5
Only bacteria with minimum 20 separate isolation are shown in the Table. IR: intrinsic resistance, AMC = co-amoxiclav; CTX = cefotaxime; CAX = ceftriaxone, CAZ = ceftazidime;
FEP = cefepime; TZP = piperacilllin tazobactam, ETP = ertapenem; MEM = meropenem; CIP = ciprofloxacin; AK = amikacin; GM = gentamicin, COL = colistin, MDR = multi-drug
resistance, Green: susceptibility rate over 90%, may be prescribed empirically even in severe infections, Yellow: susceptibility rate over 80%, may be prescribed empirically except severe
infection, Red: should not be prescribed empirically. If an isolate is susceptible in high rate to certain antibiotics it does not mean that the antibiotic is a recommended agent. If an isolate is
susceptible in low rate to certain antibiotics (e.g., Escherichia coli to ciprofloxacin) it does not mean that the agent cannot be used in selected case.
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3. Discussion
The present study reveals the bacterial spectra and susceptibility patterns of ESKAPE pathogens
in a level I ED in Hungary. As such data from Hungary has not been published before, the work
fills in an important gap in knowledge. Moreover, epidemiological reports from EDs are also scarce
internationally [30–37]. As most of these studies focus on certain infections or specimen types [31–34,37]
or only on certain bacteria or bacterial families [34,35], the possibility of meaningful benchmarking is
often limited.
However, at some point, we referred to the latest report of the European Surveillance of
Antimicrobial Resistance network (EARS-NET) [38], which compare antibiotic susceptibility data of
certain bacterial isolates (from invasive samples) across the member states, hence providing up-to-date
knowledge on resistance levels.
In this study, the most common clinical specimen was catheter-specimen urine, followed by blood
culture samples. ESKAPE organisms were responsible for 72.22% (4974/6887) of all positive bacterial
clinical isolates, and we detected the predominance of Gram-negative bacteria. The most common
isolates were from the Enterobacterales family, and within the group E. coli was the most frequently
isolated organism in urine and blood samples, while S. aureus and the Klebsiella genus was the second
most frequent organism isolated from blood culture and urine samples, respectively. A study from a
US emergency department, that similarly to our study, focused on all clinical specimens, also revealed
the dominance of Gram-negative bacteria and especially E. coli [30]. A survey from a German ED [31]
found the Enterobacterales group as the most commonly isolated pathogens in cases of true bacteremia
(59.3%), followed by S. aureus and this pathogen spectra has been found in another ED study focusing
on blood stream infections (BSI) [32]. E. coli and Klebsiella spp. were the most frequent isolate in other
ED studies focusing on urinary tract infections (UTIs) [36,39].
We also isolated Strenotrophomonas maltophilia and A. baumannii isolates from the ED patients;
this phenomenon is concerning, as these bacteria are predominantly considered as hospital-acquired
pathogens, often associated with infections in immunocompromised individuals. The isolation of
Strenotrophomonas maltophilia and Acinetobacter spp. was reported only from one epidemiological
study from EDs [30]. In an Italian hospital-based study focusing on ESKAPE pathogens in BSI,
Acinetobacter spp. was not involved in any community-acquired infections but was prevalent in
hospital acquired BISs [40].
Existing resistance classifications (MDR-XDR-PDR) have been used worldwide and they have
been praised in their utility for microbiological and epidemiological purposes [41]. Nevertheless,
many studies have pointed out that this classification system of bacteria may not correlate
well with clinical outcomes. Therefore novel resistance indicators has been introduced in the
last years: UDR and DTR (see definitions in the methods). As of recently, bacterial resistance
may be characterized into 5 resistance categories, and these categories represent a continuum
(wild-type>>UDR>>MDR>>DTR>>XDR>>PDR) (see Figure 2), reflecting on the ease of effective
antibacterial therapy selection. In this study, 55.3% of the bacterial isolates were wild type, meaning
that every second isolate possessed acquired resistance (i.e., 44.7% of isolates were considered to have
usual drug resistance-UDR). DTR resistance was detected among 0.46% of Gram-negative organisms,
but this ranged widely by taxon (A. baumanii: 41.94%, Klebsiella spp.: 0.15%, and no DTR in E. coli).
Regarding the MDR category, 23.8% of the bacterial isolates were classified as MDR, and highest rates
were observed for A. baumannii, P. mirabilis, K. pneumoniae and E. coli, respectively (Figure 1).
No published ED studies has reported the prevalence of UDR, DTR or even MDR, so we limited
our comparison to some hospital-based studies.
Two multicenter studies on bloodstream infection from US hospitals found DTR in 1% and
1.3% of isolates respectively [42,43], and, similarly to our data, it was highest in A. baumanni (18.3%
and 17.2%) and lowest in E. coli similar to our study (0.04% and 0.07%). In a Korean multicenter
study [44] on Gram-negative BSIs, significantly higher rate of isolates were classified as DTR (12.6%),
no DTR E. coli was found, and DTR was highest in A. baumannii (79.6%) [44]. However, this Korean
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study was limited to only four taxa (E. coli, K. pneumoniae, P. aeruginosa, and Acinetobacter species,
so any comparisons should be very cautiously made. Gianella et al. [45] assessed the epidemiology
and resistance characteristics of Gram-negative BSIs in Bologna, Italy; and observed the following
resistance rates: MDR: 21.9% (vs. 23.8% in our study), DTR: 11.0% (vs. 0.46% in our study). The overall
MDR rate in Gram-negative bacilli has been reported 10.67% at a tertiary care internal medicine
unit in Romania [46]. Regarding non-fermenting Gram-negative bacteria, an Italian single-center
hospital-based study, the MDR rates of P. aeruginosa was 34.8% in community-acquired infections
(vs. 13.3% in this study), while no Acinetobacter spp. was isolated from community-acquired infections.
The MDR rate of the Enterobacterales group was nearly 100% in our study, while it was 40.8 in ESBL
positive E. coli and 78.8% in ESBL positive K. pneumoniae.
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ince he millennium, several reports showed a substantial increase of Enterobacterales-producing
ESBLs and carbapenemases worldwide [38,47–49]). In our study ESBL positive Enterobacterales was
17.7%. At species-level, 31% of the K. pneumoniae were ESBL producers (i.e., ceftriaxone susceptibility
was 69%). while E. coli isolates were ESBL producers in 14%. In a recent German ED study [31]
ceftriaxone non-susceptibility among Enterobacterales in BSI was 11.1%. In the US, a single center ED
study focusing on UTI [37] reported ESBL positive E. coli rate of 5.9%, while in a Taiwan ED study
revealed ESBL positivity in 1.7% of E. coli and in 0.9% of K. pneumoniae isolated from blood. Ceftriaxone
resistance was reported at 10% in urinary E. coli isolates [36] from a US Emergency Department.
In the EARS-NET report, the EU mean of third generation cephalosporin-resistant E. coli in invasive
isolates was 15.1%, and this rate was 31.7% for K. pneumoniae. All these confirm that ESBL-producing
Gram-negative pathogens are prevalent in our ED and that this organism has been expanded to
the community setting. The study of Liu et al. confirmed that ESBP-producing isolates were more
prevalent in n rsing home residents admitted to the ED [35]. As nursing home resid nts are often
ad itted to our ED, this might partly explain the high ESBL rat at our unit.
An Italian study also co firmed the presence of ‘problematic’ pathogens in the outpatient setti g:
they have found no significant difference in the rate of ESBL-producer phenotypes in E. coli and
K. pneumoniae isolates from hospital or community onset BSIs [40]. The presence and dissemination
of ESBL-producer strains are important challenge as therapeutic opt ons for these orga isms are
limited. Additionally, infections caused by ESBL E. coli and K. pneumoniae are associated with ncreased
mortality and length of hospital stay or worse clinical outcome compared to non-ESBL-producing
isolates [50,51]. Regarding carbapenem resistance, we have detected only one K. pneumoniae isolate
resistant to meropenem, while all other Enterobacterales species were fully susceptible to carbapenems
except one P. mirabilis isolate that were resistant to imipenem and ertapenem. However, if the spread
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of ESBLs will not be contained in our setting, and the use of carbapenems will not be controlled,
which may favor the selection of carbapenemase-producing Enterobacterales in the future. Similar
carbapenem susceptibility rates among Enterobacterales were reported from other EDs [31,35,37].
Gentamicin susceptibility of E. coli isolates was 89% in the ED study of Jorgensen et al. [36],
and the study of Liu et al. from Taiwan [35] reported high amikacin susceptibility (above 90%) in
the Enterobacterales group in the isolates of ED patients. These results are comparable to the E. coli
resistance rate in this study and similar to the EU mean of aminoglycoside resistance in E. coli
(11.1%) However, for K. pneumoniae, we recorded lower (<80%) gentamicin and amikacin resistance
rates, which data correspond well to the data of the ESAC-Net report [38]. Considerably higher
aminoglycoside susceptibility rate in ESBL-positive isolates compared to ESBL negative isolates were
found in our study, similar to the ED study of Liu et al. [35]. The fluoroquinolone resistance of the
Enterobacterales group was above 30% in this study, and at species-level, it was even higher in
common pathogens like K. pneumoniae and P. mirabilis. Ciprofloxacin resistance was 22.9% in the
Enterobacterales group in the German ED [31], and E. coli resistance ranged between 23% and 25.2%
in American EDs [34,36]. Similarly, high ciprofloxacin resistance (44.9%) for the Enterobacterales
group were only reported from Taiwan (Liu et al.) [35]. The high ciprofloxacin resistance among
Gram-negative urinary isolates from outpatients has been previously reported for the university central
microbiological laboratory [52]. The high fluoroquinolones resistance level is the direct consequence of
the exceptionally high relative use of fluoroquinolones in Hungary both in the ambulatory care and in
the hospital setting [53]. All these results confirm that fluoroquinolones empiric therapy should be
avoided in the ED setting.
A. baumannii and P. aeruginosa are both opportunistic pathogens associated primarily with
healthcare-associated infections. Both species are intrinsically resistant to many antimicrobial agents.
In this study, only colistin, a “reserve antibiotic”, showed to be effective in-vitro for all tested A. baumannii
isolates. Only 55.2% of the A. baumannii isolates were susceptible to meropenem. This value is identical
to the reported value for Hungary and considerable higher than the European average (31.9% in 2018)
in the latest EARS-NET surveillance system report [38], which, in contrast to our study, encompass
only invasive isolates.
Considering P. aeruginosa isolates in this study, effective antibacterial therapy may be anticipated
in most cases using anti-pseudomonal beta-lactam agents. Interestingly, meropenem susceptibility of
P. aeruginosa was slightly lower than susceptibility to third generation cephalosporins. The presence
of carbapenem-resistant but cephalosporin-susceptible (Car-R/Ceph-S) P. aeruginosa strains has been
already reported from our university [54].
However, ciprofloxacin resistance rate exceeded 20% (i.e., susceptibility was 77.9%), and this was
slightly above the EU mean revealed by the European Surveillance [38]. A recent study focusing on a
single German ED found similar ciprofloxacin susceptibility rate (81.3%) for P. aeruginosa recovered
from blood stream infections [31]. In our study, gentamicin susceptibility was 90.1%, and amikacin
susceptibility was 96.7% in P. aeruginosa isolates. Gentamicin susceptibility was higher (96%) in
P. aeruginosa in the ED study of Draper et al. [30], while no aminoglycoside susceptibility was reported
from the study of Rothe et al. [31].
Among S. aureus isolates, 16.9% were identified as MRSA with no identifiable temporal trends.
This is identical to the EU mean (16.4%) reported in 2018 and slightly lower than the Hungarian average
(23.1%) reported by the EARS-Net. In comparison, Kao et al. from Taiwan [32] reported MRSA rate of
6.8%, Rothe et al. [31] reported a rate of 3.3% in ED isolates. Draper et al. [30] found similar MRSA
rate (19.6%) at their ED, which was slightly lower than reported for the entire hospital. The practical
consideration of MRSA isolates is the fact that resistance to other antibacterials occurred at higher rate
compared to MSSA isolates.
Regarding Enterococcus spp., no vancomycin-resistant E. faecalis isolates were detected,
while vancomycin susceptible E. faecium was only 66.7% (resistance rate 33.3%). This rate is much
higher that the EU mean resistance of E. faecium to vancomycin (17.3%) and similar to the value
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reported for Hungary (39.5%) [38]. In an Italian hospital-based study, out of the 1628 isolates from
community acquired infections, n = 19 was E. faecium and vancomycin-resistance was detected in
only 1 case, corresponding to 5.3% [40]. From a recent German ED study, no VRE was isolated [31].
All these means that if the pathogenic role of E. faecium is suspected, one should consider the possibility
of glycopeptide-resistance.
Strengths and Limitations
The present study provides the landscape of ESKAPE pathogens causing a variety of infections in
an ED over a 5-year surveillance period to serve as a basis for antimicrobial stewardship interventions.
Such an epidemiological snapshot is scarce in the literature for emergency departments, and has not
been reported from Hungary. Also, this is one of the first studies that use the novel resistance indicators
(i.e., DTR) in other than an ICU setting and other than blood stream infections.
We have to acknowledge the limitations of this research. This is a single-center study based
on a retrospective analysis of laboratory data without linkage to clinical outcome or to patient
characteristics. However, the heterogeneous patient population of this ED, the large catchment area
and high patient-turnover may allow some generalization to other EDs. Prior hospitalization is a
well-known risk factor for infection/colonization with drug-resistant bacteria. As some of the patients
may have been hospitalized before ED presentation or live in long-term care facility, means that our
data do not reflect the true prevalence (i.e., might overestimate) the true prevalence of bacteria and
AMR in the community. Also, it has been reported that culture sending may be biased by high risk
cases and treatment failures [21]. On the other hand, the high prevalence of ESKAPE bacteria among
ED patients is alarming, as it proves that the dissemination of AMR bacteria in the community has
already occurred.
4. Materials and Methods
4.1. Study Site, Data Collection and Management, Inclusion Criteria
The present retrospective study was carried out during the time period between 1st of June 2014
and 31st of July 2019 at the central Emergency Department (ED) of the Albert Szent-Györgyi Clinical
Center, a tertiary-care teaching hospital (with approx. 1800 beds), in Southern Hungary.
The level I ED of the University of Szeged has opened on the 1st of May, 2014. The ED has
annual census of nearly 40,000 adult patient visits for mainly traumatology, internal medicine,
and neurological cases. Due to geographical distances, emergency cases of gynecology, urology,
ear-nose-throat, and ophthalmology are provided at the dedicated clinics. During the study, all positive
microbiological specimens and data collected at the central ED were retrieved. Data collection
pertaining to isolates and records of “ESKAPE” bacteria were performed electronically, in the records
of the MedBakter laboratory information system (LIS) by the authors. Non-ESKAPE bacteria and
contaminants were excluded from the study. In addition, bacteria of the normal skin flora were
considered pathogenic bacteria only if the same bacteria, has been recovered from 2 or more blood
cultures with the same antibiotic-susceptibility patterns.
During data collection and analysis, only the first isolate per patient was included in the study;
however, isolates with different antibiotic-susceptibility patterns from the same patient or isolation of
similar bacteria >7 days apart were considered as different individual isolates. If the same bacteria
with identical antibiotic-susceptibility patterns have been isolated from both the urine culture and the
blood culture of the same patient on the same day, the urine specimen was removed from the analysis.
In addition, anorectal swabs, throat swabs, and vulva specimens (n = 16) taken for screening purposes
specimens positive for fungal isolates only (n = 305) and faeces samples (n = 785) were also excluded.
4.2. Laboratory Procedures, Microbial Identification
Processing of clinical samples submitted by the ED to the Institute of Clinical Microbiology was
carried out according to routine cultivation and identification guidelines of clinical bacteriology, briefly
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described below [55]. All samples were processed within 1 h of sampling. Blood culture samples,
respiratory tract samples, cerebrospinal fluid samples, and other invasive sample types were subject to
Gram-staining to assess for the presence of microorganisms and while blood cells (where relevant).
10 µL of each un-centrifuged urine sample was cultured on UriSelect chromogenic agar plates
(Bio-Rad, Berkeley, CA, USA) with a calibrated loop, according to the manufacturer’s instructions
and incubated at 37 ◦C for 24–48 h, aerobically. If the relevant pathogens presented in significant
colony count (105 < colony-forming units/mL; however, this was subject to the interpretation of the
clinical microbiologist), the plates were passed on for further processing. Aerobic and anaerobic blood
culture bottles were incubated in the BacT/ALERT 3D (bioMérieux, Marcy-l’Étoile, France) detection
system; blood culture bottles were incubated for 5 days (21 days, if endocarditis was suspected).
Positive blood cultures, respiratory tract samples, cerebrospinal fluid samples, and other invasive
sample types were routinely processed on blood agar, chocolate agar, eosine-methylene blue agar and
Sabouraud agar (purchased from bioMérieux, Marcy-l’Étoile, France); bacterial culture media were
incubated at 37 ◦C for 24–48 h, aerobically, while Sabouraud agar was incubated at 37 ◦C for 24 h and
for additional 6 days at room temperature. Positive blood cultures, cerebrospinal fluid samples and
other invasive sample types were also processed in Brain Heart Infusion broth (Oxoid, Basingstoke,
UK) and on plated on Schaedler agar (bioMerieux, Marcy l’Etoile, France) containing horse blood
5% v/v, haemin, and Vitamin K1, for the isolation of anaerobic organisms (not included in the data
analysis). The cultivation of anaerobic bacteria was carried out in line with principles in anaerobic
bacteriology, at 37 ◦C in an anaerobic chamber (Baker Ruskinn, York, UK; in an atmosphere of 90% N2,
5% H2, and 5% CO2) for at least 48 h.
Bacterial identification was carried out using the VITEK 2 Compact ID/AST (bioMérieux, Marcy-l’Étoile,
France), based on the manufacturer’s recommendations and matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS). For MALDI-TOF analysis, bacterial cells were
transferred to a stainless-steel target with a sterile toothpick, after cultivation of the respective isolates
on appropriate culture media, described previously. An on-target extraction was performed by adding
1 µL of 70% formic acid prior to the matrix. After drying at ambient temperature, the cells were covered
with 1 µL matrix (α-cyano-4-hydroxy cinnamic acid in 50% acetonitrile/2.5% trifluoro-acetic acid).
Mass spectrometry measurements were performed by the Microflex MALDI Biotyper (Bruker Daltonics,
Bremen, Germany) in positive linear mode across the m/z range of 2 to 20 kDa; for each spectrum,
240 aser shots at 60 Hz in groups of 40 shots per sampling area were collected. The MALDI Biotyper
RTC 3.1 software (Bruker Daltonics, Bremen, Germany) and the MALDI Biotyper Library 3.1 were used
for spectrum analysis [56]. Logarithmic (log) score values (ranging between 0–3.0) were determined
by the software, by automatically calculating the proportion of matching peaks and peak intensities
between the test spectrum and the reference spectra available in the database. log score values 0-1.699
were considered as ‘not reliable identification’, 1.70–2.299 were reported as ‘probable genus-level
identification’, while a score≥2.300 was considered as reliable species-level identification [57]. 16S RNA
sequencing was not utilized for identification or otherwise in the Institute during the study period.
4.3. Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing for the relevant bacterial isolates were carried out based on
the methodological recommendations and standards of the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) valid at the time of the assays. The Kirby–Bauer disk diffusion
method (Liofilchem, Abruzzo, Italy) and gradient tests (Liofilchem, Abruzzo, Italy) were performed
on Mueller–Hinton agar (MHA). Colistin susceptibility was performed using the broth microdilution
method in a cation-adjusted Mueller-Hinton broth. Susceptibilities to carbapenems and colistin were
evaluated using commercial panels (MERLIN Diagnostica, Bornheim, Germany), using cation-adjusted
Mueller–Hinton broth. In addition, for the verification of discrepant results, the VITEK 2 Compact
ID/AST (bioMérieux, Marcy-l’Étoile, France) was also utilized. The interpretation of susceptibility results
was performed based on EUCAST breakpoints valid at the time of the interpretation. Intermediate
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results were grouped with and reported as resistant. S. aureus ATCC 29213, E. faecalis ATCC 29212,
P. mirabilis ATCC 35659, E. coli ATCC 25922, P. aeruginosa ATCC 27853, A. baumannii ATCC 19606 and S.
maltophilia ATCC 13637 were used as quality control strains.
Methicillin-resistant S. aureus (MRSA) strains were detected using mannitol salt agar (MSA)
and cefoxitin (FOX) disks (<22 mm zone diameter) and PBP2’ Latex Agglutination Test Kit (Thermo
Fisher Scientific Hungary GmbH, Budapest, Hungary) [56]. If extended-spectrum beta-lactamase
(ESBL)-production was suspected [58], detection was carried out based on EUCAST recommendations
using AmpC-ESBL Detection Set (MAST Diagnostica GmbH, Reinfeld, Germany) and VITEK 2
Compact ID/AST (bioMérieux, Marcy-l’Étoile, France), according to the manufacturer’s instructions.
Vancomycin-resistance and carbapenem-resistance was suspected in case of reduced susceptibility
or resistance to the relevant agents during routine susceptibility tests; these isolates were sent to the
national reference laboratory (at the National Public Health Institute) for further processing.
Susceptibility testing included all relevant antibiotics for the respective bacteria, to allow for their
classification into resistance categories based on the criteria detailed in Section 4.4; an antibiotic was
not tested and was excluded from the analysis if intrinsic resistance was present, based on the EUCAST
Expert Rules on Intrinsic Resistance and Exceptional Phenotypes.
4.4. Definitions for the Classification of Resistance Groups
Based on the analysis of the susceptibility testing results, respective isolates were classified into
various resistance categories. An isolate was considered as wild-type (Wt) or pan-susceptible, if they
were susceptible to all tested antibiotics, excluding those where intrinsic non-susceptibility is present.
Isolates were classified in the usual drug resistance (UDR) category, if resistance was observed to
at least one agent outside of the group of antibiotics affected by intrinsic non-susceptibility [59].
Multi-drug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria
were defined according to the European Centre for Disease Prevention and Control (ECDC) and
the US Centers for Disease Control and Prevention (CDC) Expert Proposal and it was matched and
updated according to the newest EUCAST Expert Rules on Intrinsic Resistance and Exceptional
Phenotypes [41,60]. Briefly, nonsusceptibility to ≥1 agent in ≥3 antimicrobial categories were defined as
MDR, susceptibility limited to ≤2 categories were defined as XDR and resistance to all antibiotics was
defined as PDR [41]. The difficult-to-treat (DTR) resistance category was also applied for Gram-negative
bacteria, based on Kadri et al. [42], which correlates strongly with the clinical outcomes of infection.
DTR can be described as a category within MDR isolates, where resistance to all first-line agents, i.e.,
all β-lactams, including carbapenems and β-lactamase inhibitor combinations, and fluoroquinolones
is present.
4.5. Statistical Analyses
Descriptive statistical analysis (including means or medians with ranges and percentages to
characterize data) was performed using Microsoft Excel 2013 (Redmond, WA, USA, Microsoft Corp.).
R (version 4.0.1, R Foundation for Statistical Computing Vienna, Austria) program was used for data
analysis and visualization.
4.6. Ethical Considerations
This study is part of the Antimicrobial Stewardship Programme of the University and has been
approved by the Regional and Institutional Ethical Board.
5. Conclusions
The frequent isolation of ESKAPE bacteria and the detected considerable acquired resistance
among ED patients raise concern and indicate that these organisms are present/has been disseminated
in the community as well. Understanding the local epidemiology of bacterial pathogens may provide
benefits in establishing local empirical treatment protocols.
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